Isoray, Inc. announced that William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.
Perspective Therapeutics, Inc.
Equities
CATX
US46489V1044
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 USD | +1.34% | -1.31% | +275.62% |
05-15 | Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM | |
05-15 | Perspective Therapeutics Swings to Loss in Q1, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+275.62% | 886M | |
-5.31% | 181B | |
-1.21% | 108B | |
-5.53% | 66.57B | |
+1.22% | 49.95B | |
+7.03% | 43.84B | |
+4.91% | 41.71B | |
+21.96% | 31.59B | |
+14.45% | 25.3B | |
-4.81% | 23.83B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer